Vicor Technologies, Inc. (VCRT: OTCBB) Will Keep You Updated on Crucial Relationship with the United States Military
Vicor Technologies, Inc. (OTCBB: VCRT)
Vicor Technologies, Inc. (OTCBB: VCRT) is in the crucial transformative stage for a biotechnology company on the verge of becoming a viable commercial enterprise. While their rollout in civilian medical care is underway — I do NOT want to fail to point out the enormous potential of VCRT’s relationship with the United States Military.
The PD2i VS™ (Vital Sign), is in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.
I believe when we get these results VCRT will see an incredible upswing.
Pre-Hospital and Hospital Markets
The PD2i VS™ is expected to be rolled out initially with the U.S. Army and several international armed forces. Ultimately, the Company’s goal is to license the technology for inclusion in existing vital sign monitors for pre-hospital and hospital use and combat care.
Inclusion in vital sign monitors will not preclude the development of the Company’s own hardware in a size permitting easy battlefield transport by combat care providers.
PD2i-VS™ Tested by U.S. Army Institute of Surgical Research (USAISR)
Determined to minimize mortality rate of battlefield casualties, the U.S. Army Institute of Surgical Research has been working with Vicor’s PD2i-VS system through a research collaboration and has tested it against the best methodologies currently 
available. In extensive real-world testing involving several studies with data provided by the USAISR, the PD2i-VS™ has proven to be more predictive than all other compared technologies.
In Vicor’s most recent study with Army provided data, the PD2i-VS™ examined 325 civilian trauma injury victims, twenty of whom would later die of their injuries. Incredibly, the PD2i-VS™ correctly identified all twenty.
Even more importantly, of the twenty who died, conventional trauma triaging techniques had selected only six for lifesaving intervention in the field.
This suggests both that current trauma triage methods are woefully inadequate, and that the PD2i-VS™ is poised to make an extraordinary contribution to combat and trauma survival in the near future.
The very low PD2i™ values demonstrated in the chart at above right signify imminent risk of “crashing”, revealing dire need of aggressive medical intervention.
The Studies, Presentations and Collaborations between VCRT and the United States Army is SIGNIFICANT:
Collaborative Studies Continue to Show the PD2i™ Nonlinear Algorithm Enables Accurate Triage of the Seriously Wounded
Testing of the PD2i VS™ by the U.S. Army is continuing under the Company’s collaborative agreement. In the completed study of 325 civilian trauma patients, researchers found that analysis of complex heart rate complexity using the PD2i™ nonlinear algorithm and software identifies trauma patients with good sensitivity (low percentage of false negatives) and that results are similar using both “raw” or “clean” electrocardiograms (“EKG’s”). This latter point is especially important considering the real world – on the battlefield or in civilian trauma settings – in which EKG data is collected. This data for the PD2i VS™ will be used to file a 510(k) to establish a claim for a more accurate triaging of trauma patients.
Additionally, Vicor has completed the programming necessary for the PD2i VS™ to operate as a continuous vital sign monitor. In this mode, the PD2i VS™ provides an initial PD2i™ result within three minutes of collected data and then an updated status every minute thereafter. Each result is accompanied by an audible tone, and a green, yellow, or red light to indicate the patient’s change in status and alert the emergency response team of a need for aggressive and immediate lifesaving intervention. Vicor is completing the modification of the R-R detector in the Company’s software to improve its already high sensitivity and accuracy. (The accuracy of the time intervals between each heart beat “the R-R interval” is critical to the calculation of a PD2i™ value.)
The enhanced version of the continuous PD2i VS™, together with the improved RR detector should enable the USAISR to utilize the Company’s technology in an important prospective human trial.
Presentations Associated with USAISR
Andriy Batchinsky, MD, a USAISR researcher, presented findings from a study of Vicor’s PD2i VS™ at the American Heart Association’s Resuscitation Science Symposium 2009 (November 14-15, 2009). Dr. Batchinsky presented “Does Heart-Rate Complexity Analysis Work in the Real World? Changes in the Point Correlation Dimension of Heart Rate during Prehospital Lifesaving Interventions.”
This was the first presentation at a major scientific conference featuring Vicor’s proprietary PD2i™ nonlinear algorithm. The objective of “Does Heart-Rate Complexity Analysis Work in the Real World?” was to evaluate the ability of the PD2i VS™ to distinguish trauma patients receiving lifesaving interventions from those who did not based on analysis of EKGs from 325 pre-hospital trauma patients. The PD2i™ nonlinear algorithm value was calculated on both unedited (raw) and on manually verified, noise-and ectopy-free (clean) EKG sections. In conclusion, researchers found that analysis of heart rate complexity using the PD2i™ nonlinear algorithm and software identifies trauma patients with good sensitivity (low percentage of false negatives) and that results are similar using either “raw” or “clean” EKGs. Additional studies of automated trauma triage using the PD2i VS™ are planned
Additionally, Dr. Batchinsky made the following presentations of the USAISR’s continuing studies of the PD2i VS™:
“Are We Listening to Music or Noise? Use of the Lyapunov Exponent for Comprehensive Assessment of Heart Rate Complexity during Hemorrhage in Sedated Conscious Miniature Swine” 8th International Conference on Complexity in Acute Illness – August 28-30, 2009 – Palo Alto, CA
“Complexity in Animal Models” and “Continuous Complexity Analysis and Remote Battlefield Triage” International Experts of Complexity and Variability at the Bedside Round Table – August 24-25, 2009 – Wakefield, CA
“Does Heart Rate Complexity Add to Traditional Vital Signs for Trauma Patient Triage?” ATACCC 2009 Conference – August 10-12, 2009 – St. Petersburg Beach, FL
“Toward Automated Detection of Life-threatening Injury Using Comprehensive Assessment of the Electrocardiogram” Smart Monitoring 2009 Conference – August 9, 2009 – St. Petersburg Beach, FL
Journal of Critical Care
Exploration of Heart-Rate Complexity to Determine the Need for Lifesaving Intervention in Combat Casualties was published in the June 2008 Journal of Critical Care. The Company’s first collaborative effort with the U.S. Army, this study involved combat casualties for whom EKG files were analyzed by several competing methods. Vicor’s PD2i™ nonlinear algorithm was the only method that correctly identified the need for immediate life-saving intervention in all cases.
We will keep you informed on this crucial relationship between VICOR and the United States Military.
Vicor Technologies, Inc.
2300 NW Corporate Blvd.
Suite 123
Boca Raton, FL 33431
877.528-PD2i (7324)
info@vicortech.com
Disclaimer and Forward-Looking Statements
The appearance of name-brand institutions or products in this profile does not constitute endorsement by the U.S. Army Institute of Surgical Research, the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.
Forward-looking statements in this profile are based on current plans and expectations that are subject to uncertainties and risks, which could cause the Company’s future results to differ materially. The following factors, among others, could cause the Company’s actual results to differ: the Company’s ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™ (Cardiac Analyzer), the Company’s ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; the Company’s ability to continue as a going concern; the Company’s ability to successfully develop products based on the Company’s technologies, included but not limited to the Company’s ASP distribution model for the PD2i Analyzer™; the Company’s ability to obtain and maintain adequate levels of third-party reimbursement for the Company’s products; the impact of competitive products and pricing; the Company’s ability to receive regulatory approval for the Company’s products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for the Company’s technologies; the ability of third-party manufacturers to manufacture the Company’s products; the Company’s ability to retain the services of the Company’s key personnel; the Company’s ability to market and sell the Company’s products successfully; the Company’s ability to protect the Company’s intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and Vicor assume no obligation to update forward-looking statements or the reasons why actual results could differ.
Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated fifty thousand restricted common shares and seventy-two hundred dollars by the company for profile coverage for the period ending March 31, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Vicor during the promotional period.
